Birgit S. Geurts

590 total citations · 1 hit paper
15 papers, 146 citations indexed

About

Birgit S. Geurts is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Birgit S. Geurts has authored 15 papers receiving a total of 146 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Birgit S. Geurts's work include Cancer Genomics and Diagnostics (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Birgit S. Geurts is often cited by papers focused on Cancer Genomics and Diagnostics (6 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Treatments and Mutations (3 papers). Birgit S. Geurts collaborates with scholars based in Netherlands, United States and Australia. Birgit S. Geurts's co-authors include Laurien J. Zeverijn, Emile E. Voest, Gijs F. de Wit, Thomas Battaglia, Iris Mimpen, Joris van de Haar, Joleen J.H. Traets, Sten Cornelissen, Lodewyk F.A. Wessels and Edwin Cuppen and has published in prestigious journals such as Cell, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Birgit S. Geurts

14 papers receiving 145 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A pan-cancer analysis of the microbiome in metastatic cancer

2024 94 citations Thomas Battaglia, Iris Mimpen et al. Cell profile →

Peers

Birgit S. Geurts

ONCOL

PRM

BIOTE

Laurien J. Zeverijn Netherlands

Joleen J.H. Traets Netherlands

Joris L. Vos Netherlands

Rebekah Engel Australia

Wenxiao Dai China

Cuicui Kong China

Danielle Glassman United States

P. C. Yang Taiwan

Zeng Yi China

Maria Raitses‐Gurevich Israel

Laurien J. Zeverijn Netherlands

Birgit S. Geurts

95 ×1.3

ONCOL

81 ×1.3

47 ×1.6

PRM

33 ×1.2

28 ×1.1

BIOTE

Citations per year, relative to Birgit S. Geurts Birgit S. Geurts (= 1×) peers Laurien J. Zeverijn

Countries citing papers authored by Birgit S. Geurts

Since Specialization

Citations

This map shows the geographic impact of Birgit S. Geurts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgit S. Geurts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgit S. Geurts more than expected).

Fields of papers citing papers by Birgit S. Geurts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birgit S. Geurts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgit S. Geurts. The network helps show where Birgit S. Geurts may publish in the future.

Co-authorship network of co-authors of Birgit S. Geurts

This figure shows the co-authorship network connecting the top 25 collaborators of Birgit S. Geurts. A scholar is included among the top collaborators of Birgit S. Geurts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birgit S. Geurts. Birgit S. Geurts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Zeverijn, Laurien J., Joris van de Haar, Paul Roepman, et al.. (2025). The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP). ESMO Open. 10(1). 104112–104112.

Zeverijn, Laurien J., Birgit S. Geurts, Gijs F. de Wit, et al.. (2024). Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol. Clinical Cancer Research. 30(23). 5323–5332. 1 indexed citations

Henegouwen, Jade M. van Berge, Laurien J. Zeverijn, Birgit S. Geurts, et al.. (2024). Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol. Clinical Cancer Research. 30(17). 3937–3943. 1 indexed citations

Timmer, Hans, Laurien J. Zeverijn, Birgit S. Geurts, et al.. (2024). The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP). Acta Oncologica. 63. 368–372. 9 indexed citations

Zeverijn, Laurien J., Birgit S. Geurts, Vincent van der Noort, et al.. (2024). Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP). European Journal of Cancer. 202. 113988–113988. 6 indexed citations

Mehra, Niven, Laurien J. Zeverijn, Birgit S. Geurts, et al.. (2024). Efficacy and safety of olaparib in patients with tumors harboring alterations in homologous recombination repair pathway associated genes: Results from the Drug Rediscovery Protocol.. Journal of Clinical Oncology. 42(16_suppl). 3116–3116. 1 indexed citations

Geurts, Birgit S., Laurien J. Zeverijn, Jade M. van Berge Henegouwen, et al.. (2024). Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy. The Journal of Pathology. 263(3). 288–299. 4 indexed citations

Geurts, Birgit S., Laurien J. Zeverijn, Vincent van der Noort, et al.. (2024). Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol. The Lancet Regional Health - Europe. 39. 100875–100875. 16 indexed citations

Battaglia, Thomas, Iris Mimpen, Joleen J.H. Traets, et al.. (2024). A pan-cancer analysis of the microbiome in metastatic cancer. Cell. 187(9). 2324–2335.e19. 94 indexed citations breakdown →

10.

Verkerk, Karin, Laurien J. Zeverijn, Birgit S. Geurts, et al.. (2023). 1392P Safety and efficacy of crizotinib in MET mutated (METmut) advanced non-small cell lung Cancer (aNSCLC): Results from the Drug Rediscovery Protocol (DRUP). Annals of Oncology. 34. S797–S798. 3 indexed citations

11.

Schutte, Tim, et al.. (2023). Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions. The Oncologist. 28(7). e493–e497. 1 indexed citations

12.

Geurts, Birgit S., Laurien J. Zeverijn, Gijs F. de Wit, et al.. (2023). Efficacy and Safety of Panitumumab in Patients With RAF/RAS-Wild-Type Glioblastoma: Results From the Drug Rediscovery Protocol. The Oncologist. 29(5). 431–440. 3 indexed citations

13.

Zeverijn, Laurien J., Jade M. van Berge Henegouwen, Birgit S. Geurts, et al.. (2023). 1710P Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP). Annals of Oncology. 34. S933–S933. 1 indexed citations

14.

Geurts, Birgit S., Laurien J. Zeverijn, Thomas Battaglia, et al.. (2023). Efficacy and predictors of response of nivolumab in treatment-refractory MSI solid tumors: Results of a tumor-agnostic DRUP cohort.. Journal of Clinical Oncology. 41(16_suppl). 2590–2590. 4 indexed citations

15.

Zeverijn, Laurien J., Subotheni Thavaneswaran, Jade M. van Berge Henegouwen, et al.. (2023). Clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.. Journal of Clinical Oncology. 41(16_suppl). 3101–3101. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact